A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

Inclusion Criteria: * Are currently not hospitalized. (Not applicable to participants in treatment arm 22.) * Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion. (Not applicable to participants in treatment arm 22.) * Must have sample taken for test confirming viral infection no more than 3 days prior to starting the drug infusion * Are males or females, including pregnant females who agree to contraceptive requirements * Understand and agree to comply with planned study procedures * Agree to the collection of nasopharyngeal swabs and venous blood. (Not applicable to participants in treatment arms 20-21.) * The participant or legally authorized representative give signed informed consent and/or assent Participants in treatment arms 7-9, 13-14, and 18-21 ONLY * Are greater than or equal to (≥)18 years of age and must satisfy at least one of the following at the time of screening * Are pregnant * Are ≥65 years of age * Have a body mass index (BMI) ≥35 * Have chronic kidney disease (CKD) * Have type 1 or type 2 diabetes * Have immunosuppressive disease * Are currently receiving immunosuppressive treatment or * Are ≥55 years of age AND have: * cardiovascular disease (CVD), OR * hypertension, OR * chronic obstructive pulmonary disease (COPD) or other chronic respiratory disease * Are 12-17 years of age (inclusive) AND satisfy at least one of the following at the time of screening * Are pregnant * Have a body mass index (BMI) ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical\_charts.htm * Have sickle cell disease * Have congenital or acquired heart disease * Have neurodevelopmental disorders, for example, cerebral palsy * Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19) * Have asthma or reactive airway or other chronic respiratory disease that requires daily medication for control * Have type 1 or type 2 diabetes * Have chronic kidney disease * Have immunosuppressive disease, or * Are currently receiving immunosuppressive treatment Participants in treatment arm 22 ONLY \- Are 0 (≥ 32 weeks gestational age AND ≥ 1.5 kilograms \[kg\]) to 17 years of age (inclusive) AND satisfy at least one of the following risk factors at the time of screening * Are pregnant * Have a BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical\_charts.htm * Have sickle cell disease * Have congenital or acquired heart disease * Have neurodevelopmental disorders, for example, cerebral palsy, autism, or Down syndrome (FAIR Health 2020; Spreat et al. 2020) * Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19) * Have asthma, cystic fibrosis, reactive airways disease or other chronic respiratory disease that requires daily medication for control * Have type 1 or type 2 diabetes * Have chronic kidney disease * Have immunosuppressive disease, or * Are currently receiving immunosuppressive treatment, or * Are less than (\<) one year of age. * Have one or more COVID-19 symptoms * Shortness of breath/difficulty breathing * Fever * Sore throat * Nausea * Diarrhea * Tiredness * Headache * New loss of taste * Nasal congestion/runny nose * Chills * Stomachache * Vomiting * Cough * Muscle/body aches and pain * New loss of smell * Poor appetite or poor feeding (in babies) Participants in treatment arm 23 ONLY: Must have first positive result sample of current SARS-CoV-2 viral infection ≤3 days prior to start of treatment administration. Participant can have COVID previously and still meet criteria for this addendum. Positive result needs to be from a current infection. Are 0 (≥ 38 weeks gestational age and ≥ 3.3 kg) to \<12 years of age at the time of screening, or are 12 to 17 and weighing \<40 kg; and * Have mild to moderate COVID-19 disease, including one or more COVID-19 symptoms within the last 7 days * Shortness of breath/difficulty breathing * Fever * Sore throat * Nausea * Diarrhea * Tiredness * Headache * New loss of taste * Nasal congestion/runny nose * Chills * Malaise * Vomiting * Cough * Muscle/body aches and pain * New loss of smell * Poor appetite or poor feeding (in babies under 1 year old) Exclusion Criteria: * Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) less than (\<)300, respiratory rate greater than or equal to (≥)30 per minute, heart rate ≥125 per minute due to COVID-19 * Require mechanical ventilation or anticipated impending need for mechanical ventilation due to COVID-19 * Have known allergies to any of the components used in the formulation of the interventions * Have hemodynamic instability requiring use of pressors within 24 hours of randomization * Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention * Have any co-morbidity requiring surgery within \<7 days, or that is considered life-threatening within 29 days * Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study * Have a history of a positive SARS-CoV-2 test prior to the one serving as eligibility for this study * Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing * Have received treatment with a SARS-CoV-2 specific monoclonal antibody * Have received convalescent COVID-19 plasma treatment * Have participated in a previous SARS-CoV-2 vaccine study or have received a SARS-CoV-2 vaccine * Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed * Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * Mothers who are breast feeding Participants in Treatment Arm 22 ONLY * Have a diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C) in the opinion of the investigator * Are currently hospitalized for treatment of COVID-19. Other reasons for hospitalization are acceptable. Participants in treatment arm 23 ONLY * SpO2 ≤ 93% on room air at sea level, or while on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity, respiratory rate ≥30 per minute, and heart rate ≥125 per minute due to COVID-19 (FDA February 2021) * Require mechanical ventilation or anticipated impending need for mechanical ventilation due to COVID-19 * Have known allergies to any of the components used in the formulation of the interventions * Have hemodynamic instability requiring use of pressors within 24 hours of randomization * Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention * Have any co-morbidity requiring surgery within 7 days, or that is considered life-threatening within 29 days * Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study. * Have received treatment with a SARS-CoV-2 specific monoclonal antibody or remdesivir within 90 days before dosing. * Have received convalescent COVID-19 plasma treatment within 90 days before dosing * Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed * Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * Are currently pregnant or breast feeding